Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 26 of 51 September/October 2018 Clinical OMICs 25 Texas A&M hurdles and focus on real medical conditions that can truly impact health," Coté said. He also emphasized that there are three kinds of data that are patient-generated: chemical/biochemical (blood glu- cose levels), physical (blood pressure), and contextual (rest- ing, walking, running). The ideal device would gather all three kinds of data and do so redundantly so that back-up systems are available in case of failures. And, its use would begin with the gathering of baseline data. In that way, Coté said, healthcare providers could truly leverage the continu- ous data being generated by an individual. Mark Wolff, chief health analytics strategist at SAS, a maker of data analytics software, agreed with this asses- sement. "As we collect and analyze growing volumes of ever-more granular data about the diagnosis, treatment, outcomes and value of care, we are realizing the promise of true biomedical informatics. Such a wealth of data— and the ubiquity of connected devices—will ultimately drive the adoption of more intelligent clinical decision support systems." As Kvedar predicted, connected care in the new mobile era is truly becoming a reality. Devices at The Forefront If you don't count smartphones and fitness trackers, the first true wearable medical devices are continuous glucose mon- itors (CGMs). Currently, Medtronic (Guardian Sensor 3) and Abbott (FreeStyle Libre) both have CGMs on the market. Medtronic's MiniMed system includes their CGM and an insu- lin pump, making a hybrid personalized closed-loop system. Abbott has partnered with Bigfoot Biomedical to create a similar insulin pump/CGM system. CGMs rely on sensors that are worn on the back of the arm or abdomen for seven to 10 days. The devices mean that those who use them can avoid the painful finger pricks normally required to measure blood glucose. Abbott also makes Confirm RX, a smartphone com- patible insertable cardiac monitor used to diagnose patients with cardiac symptoms. There are many lessons to be learned from the makers of these front-line devices. Ali Dianaty, vice president of re- search and development for Medtronic's Diabetes Group, said the focus was on clinical outcomes during the development of the CGM sensor. Patient comfort came second. "Today, the sen- sor is small, flexible, and painless to insert. Patients wearing it don't feel it," Dianaty said. "These are the little things that drive choice and how compliant patients are." Likewise, Avi Fischer, M.D., Abbot's cardiac rhythm man- agement medical director, said he and his colleagues have learned the value of easy-engagement of patients in their own healthcare. The company conducted research among differ- ent age groups and cultures when creating the device and its smartphone app, which has now been translated into 30 to 40 languages. "The feedback we have received from patients has been almost uniformly positive. There is no use in having a de- vice out there that is not user-friendly." — Camille Mojica Rey, Ph.D. A researcher shows the "brains" of a remote monitoring device.

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018